Scout | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)

This grant opportunity seeks applications to study how bacteria, bacteriophages, and other non-cancer-causing viruses interact with tumors and the immune system, with the goal of advancing cancer imaging, treatment, and diagnostics. The focus is on using these microorganisms in various roles, such as anti-tumor agents, immune activators, or treatment and imaging delivery vehicles, complementin…

Source

Agency: National Institutes of Health

Program: SBIR

Award

Award Ceiling: $200,000

Funding Amount: $200,000

Dates

Opportunity Released: February 18, 2022

Open for Submission: February 18, 2022

Submission Deadline: May 7, 2025

Application Window Closes: May 7, 2025

Keywords

microbial-based therapy

cancer imaging

bacteria in cancer treatment

tumor diagnostics

bacteriophages

immune system interactions

microbial tumor therapy

non-oncolytic viruses

preclinical cancer studies

oral cancer therapies

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers